Publikationen (60) Publikationen von Silvestre Vicent Cambra

2024

  1. GeNNius: an ultrafast drug-target interaction inference method based on graph neural networks

    Bioinformatics (Oxford, England), Vol. 40, Núm. 1

  2. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation

    Molecular Cancer, Vol. 23, Núm. 1

2023

  1. Correction: The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer (Molecular Cancer, (2023), 22, 1, (86), 10.1186/s12943-023-01788-w)

    Molecular Cancer

  2. Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance

    Nature Reviews Gastroenterology and Hepatology, Vol. 20, Núm. 7, pp. 462-480

  3. LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 6, pp. 1137-1154

  4. Mecanismos de señalización celular

    Biología celular biomédica (Elsevier), pp. 301-328

  5. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

    Nature Medicine, Vol. 29, Núm. 3, pp. 632-645

  6. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

    Nature Communications, Vol. 14, Núm. 1

  7. TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory

    Cancer Cell, Vol. 41, Núm. 11, pp. 1911-1926.e8

  8. The Regulators of Peroxisomal Acyl-Carnitine Shuttle CROT and CRAT Promote Metastasis in Melanoma

    Journal of Investigative Dermatology, Vol. 143, Núm. 2, pp. 305-316.e5

2022

  1. Characterization of KRAS-driven NSCLC cell lines with diverse mutational landscape and assessment of their response to MYC inhibition

    European Journal of Cancer, Vol. 174, pp. S47

  2. Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis

    Cancer Letters, Vol. 529, pp. 70-84

  3. Epigenetic basis of oncogenic-Kras-mediated epithelial-cellular proliferation and plasticity

    Developmental Cell, Vol. 57, Núm. 3, pp. 310-328.e9

  4. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming

    Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1

  5. Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer

    Cancer Discovery, Vol. 12, Núm. 5, pp. 1356-1377

2021

  1. Elevated NSD3 histone methylation activity drives squamous cell lung cancer

    Nature, Vol. 590, Núm. 7846, pp. 504-508

  2. FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted

    Journal of Hepatology, Vol. 75, Núm. 2, pp. 363-376

  3. PDAC as an Immune Evasive Disease: Can 3D Model Systems Aid to Tackle This Clinical Problem?

    Frontiers in Cell and Developmental Biology, Vol. 9

  4. The transcription factor SLUG uncouples pancreatic cancer progression from the RAF–MEK1/2–ERK1/2 pathway

    Cancer Research, Vol. 81, Núm. 14, pp. 3849-3861

2020

  1. FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy

    EBioMedicine, Vol. 53